The significance of serum lgG4 and CA19-9, autoantibodies in diagnosis and differential diagnosis of lgG4-related sclerosing cholangitis

摘要

Objective: To investigate the value of serum levels of lgG4 and CA19-9, and autoantibodies in the diagnosis of lgG4-related sclerosing cholangitis (lgG4-SC). Methods: We detected the serum lgG4 and CA19-9 of 45 lgG4-SC patients, 173 non-lgG4-SC patients and 48 healthy controls by immunoassay and chemiluminescence, respectively, with antinuclear antibody (ANA), anti-neutrophil antibody (ANCA), anti-smooth muscle antibody (SMA) and anti-mitochon-drial antibody (AMA) level detected by indirect immunofluorescence. Then analyze the detection results. Results: (1) The positive rates of ANA, ANCA, SMA and AMA in patients with lgG4-SC were 40%, 6.67%, 0 and 2.22%. Among them, the positive rate of ANA was significantly higher than that of the healthy control group (p<.01), and the positive rate of ANA, ANCA, SMA and AMA were significantly different from that of the non-lgG4-SC group (p<.05). (2) Serum levels of lgG4 and CA19-9 increased significantly in patients with lgG4-SC compared with the healthy controls (p<.01). The areas under the ROC curve (AUC) of lgG4 and CA19-9 were 0.9750 and 0.6498, respectively (p<.05). Conclusion: The high levels of serum lgG4 and CA19-9, and autoantibodies detections are of great important clinical value in diagnosis and differential diagnosis of lgG4-SC.